The predictive value of body protein for chemotherapy‐induced toxicity

The use of body surface area in determining chemotherapy dosing, particularly in the obese, remains controversial. Total body nitrogen (TBN) measurement in patients with serious illness has been suggested to be an accurate predictor of clinical course. The ability of TBN to predict chemotherapy‐induced neutropenia was examined in the current study.

[1]  R. Bartsch,et al.  Adjuvant systemic therapy for early breast cancer. , 2012, Lancet.

[2]  W. Bezwoda.  Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer , 1999 .

[3]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[4]  B. Fisher,et al.  Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence. , 1998, International journal of radiation oncology, biology, physics.

[5]  M. Ratain.  Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. D. de Vries,et al.  Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. , 1996, Oncology.

[8]  M. Matsumoto,et al.  Relaxant responses by optical isomers of ephedrine and methylephedrine in guinea pig tracheal smooth muscle. , 1996, Pharmacology.

[9]  J. Baselga,et al.  Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Streat,et al.  Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. , 1996, Annals of surgery.

[11]  G. Hill,et al.  Progressive cellular dehydration and proteolysis in critically ill patients , 1996, The Lancet.

[12]  C. Pollock,et al.  Total body nitrogen as a prognostic marker in maintenance dialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[13]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[14]  S. Steinberg,et al.  Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. , 1995, Journal of the National Cancer Institute.

[15]  L. Baur,et al.  Total body nitrogen in children with chronic renal failure and short stature. , 1994, European journal of clinical nutrition.

[16]  Peters Wp,et al.  Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. , 1994 .

[17]  G. Guyatt,et al.  Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. , 1994, JAMA.

[18]  G. Guyatt,et al.  Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test: B. What Are the Results and Will They Help Me In Caring for My Patients? , 1994 .

[19]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] , 1993 .

[20]  M. Tisdale,et al.  Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. , 1993, British Journal of Cancer.

[21]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[22]  J. Radford,et al.  Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.

[23]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[24]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[25]  G. Bonadonna,et al.  Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Nooij,et al.  "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). , 1991, European journal of cancer.

[27]  G. Bonadonna,et al.  Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Baur,et al.  Nitrogen deposition in malnourished children with cystic fibrosis. , 1991, The American journal of clinical nutrition.

[29]  L. Baur,et al.  Determination of total body water by Fourier transform infrared analysis. , 1990, Australasian physical & engineering sciences in medicine.

[30]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[32]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[33]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[34]  Fagan Tj.  Letter: Nomogram for Bayes theorem. , 1975 .

[35]  J. Durnin,et al.  Total body fat, calculated from body density, and its relationship to skinfold thickness in 571 people aged 12-72 years. , 1973, The Proceedings of the Nutrition Society.

[36]  J. Durnin,et al.  An experimental study on the variability of measurements of skinfold thicknesses by three observers on twenty-three young women and twenty-seven young men. , 1971, Proceedings of the Nutrition Society.

[37]  J. Durnin,et al.  The assessment of the amount of fat in the human body from measurements of skinfold thickness , 1967, British Journal of Nutrition.

[38]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[39]  A. Auvinen,et al.  Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. , 1997, British Journal of Cancer.

[40]  E. Gallardo,et al.  Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. , 1997, Acta oncologica.

[41]  W. Peters.  Management of metastatic breast cancer. , 1995, Advances in internal medicine.

[42]  W. Peters,et al.  Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. , 1994, Current opinion in hematology.

[43]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. , 1993, Blood.

[44]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[45]  L. Baur,et al.  The role of body protein studies in clinical trials. , 1990, Basic life sciences.

[46]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[47]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.